Tag:

AstraZeneca

Latest Headlines

Latest Headlines

Takeda, AstraZeneca diabetes drugs need warnings on heart risk, FDA says

Diabetes drugs of Takeda Pharmaceutical and AstraZeneca should be labeled at risk of heart failure associated with them, a group of U.S. FDA advisers recommended. Nearly all of the members of an advisory panel voted for the added safety information on labels.

Onglyza's label should flag heart failure risks, FDA panel says

AstraZeneca escaped the worst with an FDA panel vote on Onglyza. The agency's expert advisers almost unanimously backed the drug's cardiovascular safety. But the panel also recommended that the diabetes drug's label include information about a potential risk of heart failure.

AstraZeneca taps PatientsLikeMe's network for drug R&D insights

AstraZeneca has signed on to partner with PatientsLikeMe to cull data from its network of some 250,000 patients that will help guide drug development at the pharma giant.

AstraZeneca's Onglyza 'mortality' risks noted by FDA reviewers

FDA staff reviewers have raised serious concerns about the safety of AstraZeneca's Onglyza ahead of an advisory committee review Tuesday, which could result in a recommendation of a label change for Onglyza as well as other drugs in the DPP4 inhibitor class. 

Safety scare with AstraZeneca's diabetes drug could shake up the DPP-4 field

The FDA raised some alarming concerns tied to AstraZeneca's Onglyza ahead of a committee meeting to discuss the safety of so-called DPP-4 inhibitors, sounding a worrying note for a blockbuster class of drugs.

AZ's Onglyza has most to lose at FDA safety confab, analysts say

FDA experts will grill a couple of diabetes meds next Tuesday, and the outcome of that debate could put a damper on sales. The drugs: AstraZeneca's Onglyza and Takeda's Nesina, both DPP-4 blood sugar-fighters. The questions: Do they really increase the risk of heart failure? And if so, what's to be done about it?

Regulus surges after AstraZeneca snags rights to NASH drug

Shares of Regulus spiked 10% Tuesday afternoon after its Big Pharma partner AstraZeneca stepped up to grab rights to a preclinical drug candidate for NASH with plans to steer it into clinical studies.

Regulus surges after AstraZeneca snags rights to preclinical NASH drug

Shares of Regulus spiked 10% Tuesday afternoon after its Big Pharma partner AstraZeneca stepped up to grab rights to a preclinical drug candidate for NASH with plans to steer it into clinical studies.

AstraZeneca gets FDA nod for alternative administration of oral heart med

AstraZeneca's Brilinta can now be crushed and mixed with water or delivered through the nose via a tube, the FDA said, in a move designed to help patients who are unable to swallow the 90-mg tablets whole.

AstraZeneca razes R&D facilities in Delaware

AstraZeneca's former R&D operations in Delaware, abandoned years ago in the pharma giant's ongoing restructuring and downsizing, are being razed.